

Chemical Constituents of the Marine Traditional Chinese Medicine of *Pegasus laternarius* Cuvier (Hai-E Yu)

Shuqian Sun^{1#} Zhen Gao^{2,3#} Mengxue Wang² Sha Chen² Wenjuan Guo^{1*} Xuwen Li^{2,3*}

¹ School of Chemistry and Chemical Engineering, University of Jinan, Jinan, People's Republic of China


² Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, People's Republic of China

³ State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

Address for correspondence Wenjuan Guo, PhD, School of Chemistry and Chemical Engineering, University of Jinan, 336 Nanxinhuang West Road, Jinan 250022, People's Republic of China (e-mail: chm_guojw@163.com).

Xuwen Li, PhD, Shandong Laboratory of Yantai Drug Discovery, 198 Binhai East Road, Yantai 264117, People's Republic of China (e-mail: xwli@simm.ac.cn).

Pharmaceut Fronts



Abstract

Keywords

- ▶ marine traditional Chinese medicine
- ▶ *Pegasus laternarius* Cuvier
- ▶ cytotoxicity
- ▶ anti-inflammatory

Pegasus laternarius Cuvier (Hai-E Yu) is a marine traditional Chinese medicine that has been used to treat cancers and reduce inflammation. Previous chemical investigations have only revealed the occurrence of high levels of protein, fatty acids, and a large number of steroids, thus more active compounds in *P. laternarius* still need to be further discovered. The present study aims to search for new bioactive constituents of *P. laternarius* with cytotoxic effects and nitric oxide (NO) inhibitory activities. In this work, 16 pure compounds from the ethyl acetate fraction of *Pegasus laternarius* Cuvier were successively obtained by various chromatographic techniques, and the structure of the isolates was elucidated by spectroscopic analyses. The isolated and identified

These authors contributed equally to this work.

received
November 15, 2023
accepted
April 24, 2024

DOI <https://doi.org/10.1055/s-0044-1787010>.
ISSN 2628-5088.

© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

compounds included one 2*H*-1,2,3-triazole-4-carboxylate derivative (**1**), two oxadiazines (**2**, **3**), two amino acids (**4**, **5**), three nucleosides (**6–8**), three steroids (**9–11**), and five others (**12–16**). All the obtained compounds were evaluated for their antitumor activity on A549 and HCT-116 cell lines along with their inhibitory effects on lipopolysaccharide-induced NO production in RAW264.7 cells. The triazole compound **1** was found to exhibit moderate cytotoxicity against two human cell lines (A549 and HCT-116) with IC₅₀ values of 44.5 and 32.9 μmol/L, respectively. The steroid compound **10** inhibited NO production with IC₅₀ values lower than 50 μmol/L. Consequently, this study provides insight into the cytotoxic and NO inhibitory activities of the marine traditional Chinese medicines in Hai-E-Yu.

Introduction

Marine organisms tend to produce unique secondary metabolites with specific activities due to the special marine environment characteristics of high salt, high pressure, low nutrition, lack of oxygen, and lack of sunlight, which could be considered the newest source of bioactive natural products in relation to terrestrial plants and nonmarine microorganisms.¹ Among them, a variety of species (seaweeds, shellfishes, and minerals) have been used for thousands of years as marine traditional Chinese medicines (MTCMs) to treat diseases, and modern pharmacological studies have shown that they have antitumor, anti-inflammatory, and antiviral properties.² Currently, it has become an important medicinal resource for the development of new drugs for the prevention and treatment of difficult medical issues. For instance, *Concha Ostreae* polysaccharides can boost the immune system, *Sargassum* has the effects on antitumor and antiviral therapy, and *Hippocampus* exhibits a great effect on antiaging. The *in vitro* cellular studies have also suggested that the water-soluble *Margaritifera concha* protein has a strong effect on stimulating the differentiation of bone marrow stromal cells into osteoblasts and increased osteoblast proliferation.³ Notably, a type of sulfated polysaccharide derived from seaweed has been used clinically for cardiovascular diseases, and sodium oligomannate (GV-971), an oligosaccharide compound derived from brown algae, has been used for the treatment of Alzheimer's disease by targeting the brain-gut axis.⁴ Therefore, it is of great value to discover novel compounds with diverse biological activities from MTCMs.

Pegasus laternarius Cuvier (Hai-E Yu) is an MTCM commonly used for the treatment of tumors, cough, and antiarrheal, and is documented in Chinese Pharmacopoeia. Previous studies have shown that the extracts of *P. laternarius* exhibited antitumor activity, anti-lipid peroxidation effect, memory-improving effect, etc. However, the constituents of *P. laternarius* have less been investigated. The previous chemical investigations have only confirmed the occurrence of a high level of protein, fatty acids, and a large number of steroids. We anticipated that more active compounds in *P. laternarius* will be further explored. In our continuing efforts to search for cytostatic and anti-inflammatory compounds from MTCMs, the chemical investigation

on *P. laternarius* was undertaken and resulted in the isolation and identification of 16 compounds (►Fig. 1), among them, the occurrences of compounds **1**, **6**, **12**, and **13** were first reported from *P. laternarius*. In bioassay, the 2*H*-1,2,3-triazole-4-carboxylate compound **1** showed moderate cytotoxicity with IC₅₀ values of 44.5 and 32.9 μmol/L on the A549 and HCT-116 cell lines, while the steroid compound **10** inhibited NO production with IC₅₀ values lower than 50 μmol/L. Herein, the isolation, structural determination, and assessment of the cytostatic and anti-inflammatory activities of the isolated compounds are further described.

Results and Discussion

Extraction and Isolation

The air-dried whole parts of *Pegasus laternarius* Cuvier (483 g) were powdered and extracted with dichloromethane/methanol (CH₂Cl₂/MeOH, 1:1) five times at room temperature. The crude extracts were concentrated by evaporation under reduced pressure to yield 73 g of dry extract. The obtained dry extracts were suspended in H₂O and partitioned successively with petroleum ether (PE), ethyl acetate (EtOAc), and *n*-butyl alcohol (*n*-BuOH, 1L × 5, five times). The EtOAc extract (10.8 g) was subjected to a silica gel column (Si CC, 200–300 mesh; PE/EtOAc, 20:1, 10:1, 5:1, 2:1, 1:1, v/v; CH₂Cl₂/MeOH, 15:1, 10:1, 5:1, 2:1, v/v) as an eluent to obtain six fractions, labeled as Fr. 1 to Fr. 6. The fraction Fr.3 (1.05 g) was submitted to silica gel column with PE/CH₂Cl₂ (95:5–50:50, v/v), leading to two new fractions, in which fraction Fr. 3–1 (104 mg) was purified by silica gel column with gradient of PE/EtOAc (90:10–50:50, v/v) to afford compound **9** (37.7 mg). The fraction Fr. 5 (0.64 g) was further submitted to silica gel column with PE/EtOAc (95:5–50:50, v/v) leading to two new fractions, Fr. 5–1 and Fr. 5–2, which were then subjected to preparative high-performance liquid chromatography (HPLC) with a solvent system of MeOH/H₂O (60:40, v/v) to provide compound **12** (*t*_R = 16 minutes, 3.4 mg) and **13** (*t*_R = 35 minutes, 2.8 mg), respectively. The fraction Fr. 6 (1.60 g) was subjected to a C18 reversed-phase column eluted with MeOH/H₂O (30:70–100:0, v/v) to yield five new fractions. The fraction Fr. 6–4 (159 mg) was chromatographed on Sephadex LH-20 (CH₂Cl₂/MeOH, 1:1, v/v) to afford three new fractions. The fraction Fr. 6–4–3 (65 mg) was purified by silica gel column and eluted with




Fig. 1 Chemical structures of the isolated and identified compounds 1–16.

CH₂Cl₂/MeOH (90:10–50:50, v/v) to afford the steroid compound **10** (4.5 mg). The PE extract (38.7 g) was subjected to a silica gel column using PE/CH₂Cl₂ (98:2–0:100, v/v) as an eluent to obtain seven new fractions, S.1–S.7. The fraction S.4 (1.16 g) was submitted to silica gel column with PE/CH₂Cl₂ (90:10–0:100, v/v) leading to five new fractions. The fraction S.4–1 (59 mg) was purified by a silica gel column with a gradient of PE/CH₂Cl₂ (90:10–70:30, v/v) to afford the phthalate ester compound **14** (3.6 mg) as well as the terephthalate compound **15** (20.2 mg). The 2*H*-1,2,3-triazole-4-carboxylate **1** (12.8 mg) was obtained from fraction S.5. The fraction S.7 (100 mg) was submitted to the silica gel column with PE/EtOAc (98:2–50:50, v/v) leading to three new fractions. The fraction S.7–1 (30 mg) was subjected to preparative HPLC (MeOH/H₂O, 80:20, v/v) leading to the octadecatrienoic acid **16** (*t*_R = 20 minutes, 3.1 mg). The S.7–3 was chromatographed on Sephadex LH-20 (CH₂Cl₂/MeOH, 1:1, v/v) to afford three new fractions, in

which the fraction S.7–3–2 (50 mg) was purified by silica gel column with a gradient of PE/CH₂Cl₂ (95:5–60:40, v/v) to afford nucleoside **6** (4.6 mg) and cholesterol **11** (2.2 mg). The *n*-BuOH alcohol (7.09 g) was subjected to a silica gel column using CH₂Cl₂/MeOH (98:2–0:100, v/v) as an eluent to obtain five fractions, Z.1–Z.5. The fraction Z.3 (1.0 g) was subjected to a Si CC (CH₂Cl₂/MeOH, 95:5–5:5, v/v) followed by semipreparative HPLC (MeOH/H₂O, 10:90, v/v) to obtain the pyrimidine-2,4-dione compounds **2** (*t*_R = 15 minutes, 5 mg) and **3** (*t*_R = 8 minutes, 13 mg). The fraction Z.3 (60 mg) was chromatographed on Sephadex LH-20 (CH₂Cl₂/MeOH, 1:1, v/v) to afford three new fractions. The fraction Z.3–2 (30 mg) was subjected to preparative HPLC (MeOH/H₂O, 10:90, v/v) leading to *D*-phenylalanine **4** (*t*_R = 12 minutes, 2.1 mg) and *L*-tryptophan **5** (*t*_R = 8 minutes, 1.8 mg). Finally, the fraction Z.5 (42 mg) was purified by preparative HPLC (MeOH/H₂O, 10:90, v/v) to yield the deoxynucleosides **7** (*t*_R = 9 minutes, 1.2 mg) and **8** (*t*_R = 16 minutes, 3.1 mg).

(R)-2-Propylhexyl 2H-1,2,3-triazole-4-carboxylate (compound 1): yellow oil, $C_{12}H_{21}N_3O_2$, 1H NMR (400 MHz, $CDCl_3$) δ_H 8.09 (s, 1H, NH), 8.09 (s, 1H, H-5), 4.31–4.22 (m, 2H, H-1'), 1.73 (t, $J = 6.2$ Hz, 1H, H-2'), 0.95 (t, $J = 7.5$ Hz, 3H, H-3''), 0.90 (t, $J = 7.0$ Hz, 3H, H-6'). ^{13}C NMR (100 MHz, $CDCl_3$) δ_C 134.40 (C-4), 129.64 (C-5), 166.12 (C-6), 67.92 (C-1'), 39.06 (C-2'), 29.84 (C-3'), 29.13 (C-4'), 23.11 (C-5'), 14.17 (C-6'), 30.72 (C-1''), 24.13 (C-2''). The data were consistent with a reported study.⁵

Thymine (compound 2): white powder, $C_5H_6N_2O_2$, 1H NMR (600 MHz, $DMSO-d_6$) δ_H 10.98 (s, 1H, NH), 10.58 (s, 1H, NH), 7.24 (s, 1H, H-6), 1.72 (s, 3H, H-7). ^{13}C NMR (150 MHz, $DMSO-d_6$) δ_C 164.95 (C-4), 151.52 (C-2), 137.74 (C-6), 107.69 (C-5), 11.82 (C-7). The data were consistent with a reported study.⁶

Uracil (compound 3): white powder, $C_4H_4N_2O_2$, 1H NMR (600 MHz, $DMSO-d_6$) δ_H 11.00 (s, 1H, NH), 10.81 (s, 1H, NH), 7.38 (d, $J = 7.6$ Hz, 1H, H-6), 5.44 (d, $J = 7.6$ Hz, 1H, H-5). ^{13}C NMR (150 MHz, $DMSO-d_6$) δ_C 164.37 (C-4), 151.55 (C-2), 142.22 (C-6), 100.25 (C-5). The data were consistent with a reported study.⁶

D-Phenylalanine (compound 4): white powder, $C_9H_{11}NO_2$, 1H NMR (400 MHz, D_2O) δ_H 7.22 (m, 1H, H-2), 7.21 (m, 1H, H-1, 3, 4 and 6), 4.05 (m, 1H, H-8), 3.18 (m, 2H, H-7a), 3.02 (m, 2H, H-7b). ^{13}C NMR (100 MHz, D_2O) δ_C 174.81 (C-9), 135.47 (C-5), 129.42 (C-1 and C-3), 129.11 (C-4 and C-6), 127.64 (C-2), 56.22 (C-8), 36.82 (C-7). The data were consistent with a reported study.⁷

L-Tryptophan (compound 5): white powder, $C_{11}H_{12}N_2O_2$, 1H NMR (400 MHz, CD_3OD) δ_H 7.70 (d, $J = 7.9$ Hz, 1H, H-1), 7.36 (d, $J = 8.1$ Hz, 1H, H-4), 7.19 (s, 1H, H-8), 7.12 (t, $J = 7.5$ Hz, 1H, H-3), 7.05 (t, $J = 7.5$ Hz, 1H, H-2), 3.86 (dd, $J = 9.3, 4.0$ Hz, 1H, H-10), 3.52 (dd, $J = 15.2, 4.1$ Hz, 1H, H-9a), 3.15 (dd, $J = 15.2, 9.4$ Hz, 1H, H-9b). ^{13}C NMR (100 MHz, CD_3OD) δ_C 138.43 (C-5), 128.51 (C-6), 125.13 (C-8), 120.13 (C-3), 119.35 (C-2), 112.44 (C-4), 28.54 (C-9). The data were consistent with a reported study.⁸

2-Hydroxypurine nucleoside (compound 6): white powder, $C_{10}H_{12}N_4O_5$, 1H NMR (400 MHz, D_2O) δ_H 8.26 (s, 1H, H-8), 8.16 (s, 1H, H-6), 6.05 (d, $J = 5.8$ Hz, 1H, H-1'), 4.43 (dd, $J = 6.4, 2.6$ Hz, 1H, H-3'), 4.30–4.25 (m, 1H, H-4'), 3.91 (dd, $J = 12.8, 1.5$ Hz, 1H, H-5'a), 3.83 (dd, $J = 12.8, 3.9$ Hz, 1H, H-5'b). ^{13}C NMR (100 MHz, D_2O) δ_C 160.86 (C-2), 148.62 (C-4), 148.00 (C-6), 139.85 (C-8), 124.75 (C-5), 88.42 (C-1'), 85.67 (C-4'), 73.92 (C-3'), 70.53 (C-2'), 61.43 (C-5'). The data were consistent with a reported study.⁹

2'-Deoxyuridine (compound 7): white solid, $C_9H_{12}N_2O_5$, 1H NMR (600 MHz, $DMSO-d_6$) δ_H 7.85 (d, $J = 8.1$ Hz, 1H, H-6), 6.15 (dd, $J = 7.5, 6.2$ Hz, 1H, H-1'), 5.63 (d, $J = 8.1$ Hz, 1H, H-5), 4.23 (dt, $J = 6.2, 3.2$ Hz, 1H, H-3'), 3.79–3.76 (m, 1H, H-4'), 3.57 (dd, $J = 11.9, 3.8$ Hz, 1H, H-5'a), 3.53 (dd, $J = 11.9, 3.8$ Hz, 1H, H-5'b), 2.12–2.03 (m, 2H, H-2'). ^{13}C NMR (150 MHz, $DMSO-d_6$) δ_C 163.17 (C-4), 150.48 (C-2), 140.55 (C-6), 100.78 (C-5), 87.44 (C-4'), 84.15 (C-1'), 70.44 (C-3'), 61.31 (C-5'), 48.63 (C-2'). The data were consistent with a reported study.¹⁰

Thymidine (compound 8): white solid, $C_{10}H_{14}N_2O_5$, 1H NMR (600 MHz, $DMSO-d_6$) δ_H 7.69 (d, $J = 1.3$ Hz, 1H, H-6),

6.16 (dd, $J = 7.6, 6.2$ Hz, 1H, H-1'), 4.23 (dt, $J = 6.2, 3.1$ Hz, 1H, H-3'), 3.75 (dd, $J = 3.6$ Hz, 1H, H-4'), 3.61–3.52 (m, 2H, H-5'), 2.11–2.03 (m, 2H, H-2'), 1.76 (d, $J = 1.3$ Hz, 3H, 5- CH_3). ^{13}C NMR (150 MHz, $DMSO-d_6$) δ_C 163.83 (C-4), 150.54 (C-2), 136.20 (C-6), 109.45 (C-5), 87.32 (C-4'), 83.82 (C-1'), 70.51 (C-3'), 61.41 (C-5'), 39.49 (C-2') 12.33 (5- CH_3). The data were consistent with a reported study.¹⁰

(3 β)-Cholest-5-en-3-ol (compound 9): white amorphous powder, $C_{27}H_{46}O$, 1H NMR (400 MHz, $CDCl_3$) δ_H 5.34 (d, $J = 5.4$ Hz, 1H, H-6), 3.57 (m, 1H, H-3), 1.00 (s, 3H, H-19), 0.91 (d, $J = 6.5$ Hz, 3H, H-21), 0.87 (d, $J = 1.8$ Hz, 3H, H-26), 0.85 (d, $J = 1.8$ Hz, 3H, H-27), 0.67 (s, 3H, H-18). ^{13}C NMR (100 MHz, $CDCl_3$) δ_C 140.84 (C-5), 121.78 (C-6), 71.87 (C-3), 56.85 (C-14), 56.25 (C-17), 50.22 (C-9), 39.87 (C-16), 39.60 (C-24), 37.34 (C-1), 36.58 (C-10), 36.28 (C-22), 35.87 (C-8 and C-20), 31.99 (C-7), 31.73 (C-2), 28.31 (C-12), 28.09 (C-25), 24.37 (C-15), 23.92 (C-24), 22.90 (C-27), 22.64 (C-26), 21.17 (C-11), 19.48 (C-19), 18.80 (C-21), 11.94 (C-18). The data were consistent with a reported study.¹¹

Methyl-3 $\alpha,7\alpha$ -dihydroxy-5 β -cholan-24-oate (compound 10): colorless gelatinous solid, $C_{25}H_{42}O_4$, 1H NMR (400 MHz, $CDCl_3$) δ_H 3.84 (m, 1H, H-7), 3.68 (s, 3H, H-1'), 3.46 (m, 1H, H-3), 0.93 (d, $J = 6.5$ Hz, 3H, H-21), 0.89 (s, 3H, H-19), 0.65 (s, 3H, H-18). ^{13}C NMR (100 MHz, $CDCl_3$) δ_C 177.84 (C-24), 72.20 (C-3), 68.73 (C-7), 35.20 (C-17), 50.60 (C-14), 42.87 (C-13), 41.61 (C-5), 40.01 (C-12), 39.77 (C-4), 39.57 (C-8), 35.50 (C-1 and C-20), 35.19 (C-6 and C-10), 32.98 (C-9), 30.94 (C-2), 30.79 (C-22), 30.74 (C-23), 28.29 (C-16), 23.85 (C-15), 22.91 (C-19), 20.72 (C-11), 18.38 (C-21), 11.92 (C-18), 55.9 (C-1'). The data were consistent with a reported study.¹²

Cholest-4-en-3-one (compound 11): white solid, $C_{27}H_{44}O$, 1H NMR (400 MHz, $CDCl_3$) δ_H 5.72 (s, 1H, H-4), 1.25 (s, 2H, H-24), 1.17 (s, 3H, H-19), 0.90 (d, $J = 6.5$ Hz, 3H, H-21), 0.87 (d, $J = 1.8$ Hz, 3H, H-27), 0.85 (d, $J = 1.8$ Hz, 3H, H-26), 0.70 (s, 3H, H-18). ^{13}C NMR (100 MHz, $CDCl_3$) δ_C 199.79 (C-3), 171.85 (C-5), 123.82 (C-4), 56.19 (C-17), 55.96 (C-14), 53.90 (C-9), 42.47 (C-13), 39.71 (C-12), 39.57 (C-24), 38.69 (C-10), 36.19 (C-22), 35.83 (C-20), 35.76 (C-1), 35.70 (C-8), 34.06 (C-2), 33.03 (C-6), 32.13 (C-7), 28.25 (C-25), 28.08 (C-16), 24.25 (C-15), 23.89 (C-23), 22.88 (C-27), 22.62 (C-26), 21.10 (C-11), 18.71 (C-21), 17.46 (C-19), 12.02 (C-18). The data were consistent with a reported study.¹³

Matriisobenzofuran (compound 12): yellow powder, $C_{13}H_{14}O_3$, 1H NMR (400 MHz, $CDCl_3$) δ_H 8.18 (d, $J = 1.6$ Hz, 1H, H-7), 7.94 (dd, $J = 8.6, 1.8$ Hz, 1H, H-5), 7.49 (d, $J = 8.6$ Hz, 1H, H-4), 6.66 (s, 1H, H-8), 2.66 (s, 3H, H-10), 1.70 (s, 6H, 3- CH_3). ^{13}C NMR (100 MHz, $CDCl_3$) δ_C 197.91 (C=O, C-9), 164.94 (C-1), 157.54 (C-6), 132.93 (C-3a), 128.66 (C-7a), 125.08 (C-5), 122.54 (C-7), 111.40 (C-4), 101.17 (C-8), 69.55 (C-3), 28.94 (3- CH_3), 27.02 (C-10). The data were consistent with a reported study.¹⁴

6-Hydroxy-6-methylocta-3,7-dien-2-one (compound 13): colorless oil, $C_9H_{14}O_2$, 1H NMR (400 MHz, $CDCl_3$) δ_H 6.81 (dt, $J = 15.3, 7.5$ Hz, 1H, H-5), 6.11 (d, $J = 16.0$ Hz, 1H, H-6), 5.95 (dd, $J = 17.3, 10.7$ Hz, 1H, H-2), 5.26 (d, $J = 17.3$ Hz, 1H, H-1a), 5.12 (d, $J = 10.7$ Hz, 1H, H-1b), 2.47 (d, $J = 7.2$ Hz, 2H, H-4), 2.26 (s, 3H, H-8), 1.34 (s, 3H, H-9). ^{13}C NMR

(100 MHz, CDCl₃) δ_C 198.54 (C=O, C-7), 144.05 (C-2), 143.36 (C-5), 134.19 (C-6), 112.77 (C-1), 72.77 (C-3), 45.16 (C-4), 27.91 (C-8), 26.91 (C-9). The data were consistent with a reported study.¹⁵

Bis(2-ethylhexyl) phthalate (compound 14): colorless gelatinous solid, C₂₄H₃₈O₄, ¹H NMR (400 MHz, CDCl₃) δ_H 7.71 (dd, *J* = 5.7, 3.3 Hz, 2H, H-3'' and H-6''), 7.53 (m, 2H, H-4'' and H-5''), 4.31–4.16 (m, 2H, H-1 and H-1'), 1.74–1.64 (m, 2H, H-2 and H-2'), 0.92 (m, 6H, H-6 and H-6'), 0.90 (m, 6H, H-8 and H-8'), ¹³C NMR (100 MHz, CDCl₃) δ_C 167.92 (2C=O), 132.62 (C-1'' and C-2''), 131.03 (C-4'' and C-5''), 128.96 (C-3'' and C-6''), 68.32 (C-1 and C-1'), 38.89 (C-2 and C-2'), 30.52 (C-3 and C-3'), 29.08 (C-4 and C-4'), 23.91 (C-7 and C-7'), 23.14 (C-5 and C-5'), 14.20 (C-8 and C-8'), 11.11 (C-6 and C-6'). The data were consistent with a reported study.¹⁶

Bis(2-ethylhexyl) terephthalate (compound 15): yellow oil, C₂₄H₃₈O₄, ¹H NMR (400 MHz, CDCl₃) δ_H 8.10 (s, 4H, H-2, 3, 5 and 6), 4.32–4.21 (m, 4H, H-1' and H-1''), 1.80–1.67 (m, 2H, H-2' and H-2''), 1.47–1.27 (m, 16H, H-3', 5', 6', 7' and H-3'', 5'', 6'', 7''), 0.97–0.92 (m, 6H, H-8' and H-8''), 0.92–0.88 (m, 6H, H-4' and H-4''). ¹³C NMR (100 MHz, CDCl₃) δ_C 166.08 (C-7 and C-8), 134.38 (C-1 and C-4), 129.62 (C-2, 3, 5 and 6), 67.89 (C-1'), 39.04 (C-2'), 30.70 (C-3'), 29.11 (C-4'), 24.11 (C-7'), 23.09 (C-5'), 14.15 (C-6'), 11.21 (C-8'). The data were consistent with a reported study.¹⁷

(S,9E,13Z,15E)-12-Hydroxyoctadeca-9,13,15-octadecatrienoic acid (compound 16): yellow oil, C₁₈H₃₀O₃, ¹H NMR (400 MHz, CD₃CD) δ_H 6.00 (dd, *J* = 15.2, 11.0 Hz, 1H, H-14), 5.46 (t, *J* = 11.0 Hz, 1H, H-15), 5.14 (dd, *J* = 15.2, 6.6 Hz, 1H, H-10), 0.46 (t, *J* = 7.5 Hz, 3H, H-18). ¹³C NMR (100 MHz, CD₃CD) δ_C 175.50 (C-1), 136.68 (C-13), 134.58 (C-16), 133.05 (C-9), 129.34 (C-15), 126.65 (C-14), 125.55 (C-10), 73.27 (C-12), 36.29 (C-11), 34.94 (C-2), 30.70 (C-7), 30.25 (C-6), 30.17 (C-4), 30.11 (C-5), 28.61 (C-3), 25.99 (C-8), 21.70 (C-17), 14.56 (C-18). The data were consistent with a reported study.¹⁸

All the isolates were evaluated for their antitumor activity on A549 and HCT-116 cell lines and their inhibitory effects on lipopolysaccharide (LPS)-induced NO production in RAW264.7 cells. Inhibiting NO production in LPS-stimulated RAW 264.7 cells represents a possible way to screen agents with anti-inflammatory activity.¹⁹ The bioassay screening results indicated that the 2*H*-1,2,3-triazole-4-carboxylate derivative **1** displayed cytotoxicity with IC₅₀ values at 44.5 and 32.9 μmol/L on the A549 and HCT-116 cell lines (► **Table 1**), respectively. In addition, the steroid compound **10** inhibited NO production with an IC₅₀ value at 44.5 μmol/L (► **Table 2**), suggesting the anti-inflammatory activity of the compound.

Table 1 Cytotoxicity of compound **1** from *P. laternarius*

Compds.	IC ₅₀ (μmol/L) ^a	
	A549	HCT-116
1	44.5 ± 1.1	32.9 ± 0.7
Sorafenib ^b	12.6 ± 0.2	10.3 ± 0.5

^aData were expressed as means ± standard deviation (*n* = 3).

^bSorafenib was used as a positive control.

Table 2 Nitric oxide inhibition of compound **10** in RAW264.7 cells

Compds.	IC ₅₀ (μmol/L) ^a
10	44.5 ± 1.1
Dexamethasone ^b	20.3 ± 0.8

^aData were expressed as means ± standard deviation (*n* = 3).

^bDexamethasone was used as a positive control.

Conclusion

Chemical investigations on *Pegasus laternarius* (Hai-E Yu) were undertaken, and 16 compounds were isolated and identified. Among them, compounds **1**, **6**, **12**, and **13** were first reported from *P. laternarius*. The bioassay results showed that the triazole compound **1** exhibited moderate cytotoxicity with IC₅₀ values of 44.5 and 32.9 μmol/L on the A549 and HCT-116 cell lines, respectively, while the steroid compound **10** showed NO production inhibition activity with IC₅₀ value at concentration lower than 50 μmol/L. This study provides valuable information for understanding the MTCM of Hai-E Yu and searching for anticancer and anti-inflammatory candidates from MTCMs.

Experimental Section

General Experimental Procedures

¹H and ¹³C NMR spectra were acquired on a Bruker AVANCE III 400 and 600 spectrometer. HRESIMS spectra were recorded on an Agilent G6250 Q-TOF (Agilent, Santa Clara, California, United States). All solvents used for column chromatography and HPLC were of analytical grade (purchased from Shanghai Chemical Reagents Co., Ltd., Shanghai, China) and chromatographic grade (purchased from Dikma Technologies Inc., Beijing, China), respectively. Sephadex LH-20 (Pharmacia, Peapack, New Jersey, United States) was also used for column chromatography. Commercial silica gel (Qingdao Haiyang Chemical Co., Ltd., Qingdao, China, 100–200 and 300–400 mesh) was used for column chromatography, and precoated silica gel GF254 plates (Sinopharm Chemical Reagent Co., Shanghai, China) were used for analytical thin-layer chromatography. Reversed-phase HPLC was performed on an Agilent 1260 series liquid chromatograph equipped with a DAD G1315D detector at 210 nm (Agilent, Santa Clara, California, United States). An Agilent semipreparative XDB-C18 column (5 μm, 250 mm × 9.4 mm) was employed for the purification.

Animal Materials

The animal *Pegasus laternarius* Cuvier was collected from Yangjiang City, Guangdong Province, China in July 2022, and was authenticated by Dr. Lin Gong (Institute of Oceanology, Chinese Academy of Sciences). For reference and future studies, a voucher specimen of the animal was cataloged (No. 202207–16) in Laboratory 1808 of Shandong Laboratory of Yantai Drug Discovery.

Cytotoxicity Assay

This part was conducted by referring to our previous paper.²⁰ The materials used in the study were CCK8 kit (Shanghai Lfe-iLab Biotechnology Co., Ltd., Shanghai, China), human lung carcinoma cell line A549 and colon cancer cell line HCT-116 (Shanghai Beyotime Biotechnology, Shanghai, China), and sorafenib (Promega, <https://www.promega.com.cn/>). OD at 450 nm was measured to assess cell viability with the inhibitory ratios calculated as $[A_{(\text{control})} - A_{(\text{sample})}] / A_{(\text{control})} \times 100\%$. GraphPad Prism 7 (GraphPad Software, San Diego, CA, United States) was used to calculate IC₅₀ values. All data were expressed as the mean \pm standard deviation of three independent experiments.

Determination of NO Production and the Cell Viability Assay

The experiment was conducted according to a reported study.¹⁹ Dexamethasone was used as a control drug (Promega, <https://www.promega.com.cn/>). The NO production level was identified by measuring the nitrite concentration in the cell culture supernatants. In brief, the RAW264.7 cells (10⁵ cells/well) were stabilized with or without 1 $\mu\text{g}/\text{mL}$ of LPS for 24 hours in the presence or absence of the test compounds. Then the cell culture supernatant (100 μL) was reacted with 100 μL of Griess reagent. The viability of the remaining cells after the Griess assay was detected by colorimetric assay using CCK8. The compounds were tested for NO assay at a concentration of 50 $\mu\text{mol}/\text{L}$. If the NO inhibition of compounds in RAW264.7 cells was more than 50% at 50 $\mu\text{mol}/\text{L}$, the IC₅₀ values were tested, and the concentrations were set as 100, 50, 20, 10, 5, 1, 0.1 $\mu\text{mol}/\text{L}$, respectively.

Supporting Information

Spectroscopic characterization processes (¹H NMR and ¹³C NMR) for compounds **1–16** are included in the Supporting Information (**–Figs. S1–S32** [available in the online version]).

Ethical Approval

None declared.

Funding

This work was supported by the National Key Research and Development Program of China (Grant No. 2021YFF0502400), the Shanghai Rising-Star Program (Grant No. 20QA1411100), “Youth Innovation Promotion Association” of the Chinese Academy of Sciences (Grant No. Y202065), Youth Fund from Natural Science Foundation of Shandong Province (Grant No. ZR2023QD162), and the Shandong Science and Technology Major Project of Innovation and Entrepreneurship Community with Antibody-drug (Grant No. E321020).

Conflict of Interest

None declared.

References

- Montaser R, Luesch H. Marine natural products: a new wave of drugs? *Future Med Chem* 2011;3(12):1475–1489
- Wang Y, Xing M, Cao Q, Ji A, Liang H, Song S. Biological activities of fucoidan and the factors mediating its therapeutic effects: a review of recent studies. *Mar Drugs* 2019;17(03):183
- Cao W, Liu J, Dai Y, Zhou Y, Li R, Yu P. Bibliometric analysis of marine traditional Chinese medicine in Pharmacopoeia of the People's Republic of China: development, differences, and trends directions. *Evid Based Complement Alternat Med* 2022; 2022:3971967
- Wang T, Kuang W, Chen W, et al. A phase II randomized trial of sodium oligomannate in Alzheimer's dementia. *Alzheimers Res Ther* 2020;12(01):110
- Nguyen NT, Dang PH, Vu NXT, Le TH, Nguyen MTT. Quinoliumolate and 2H-1,2,3-triazole derivatives from the stems of *Paramignya trimera* and their α -glucosidase inhibitory activities: *in vitro* and *in silico* studies. *J Nat Prod* 2017;80(07): 2151–2155
- Nollet AJH, Koomen GJ, Grose WFA, Pandit UK. Application of NMR spectroscopy in distinguishing between N1- and N3-substituted 2,4-dioxo-1,2,3,4-tetrahydropyrimidines. *Tetrahedron Lett* 1969;10(53):4607–4608
- Tian J, Yin Y, Sun H, Luo X. Magnesium chloride: an efficient ¹³C NMR relaxation agent for amino acids and some carboxylic acids. *J Magn Reson* 2002;159(02):137–144
- Malta BLF, Senra DJ, Tinoco WL, Medeiros EM, Antunes ACO. Chiral recognition of 2-hydroxypropyl- α -cyclodextrin towards DL-tryptophan. *Lett Org Chem* 2009;6(03):258–263
- Secrist JA, Shortnacy-Fowler AT, Bennett LL, Montgomery JA. Synthesis and biologic evaluation of 8-substituted derivatives of nebularine (9- β -D-ribofuranosylpurine). *Nucleosides Nucleotides* 1994;13(05):1017–1029
- Kline PC, Serianni AS. Chiral hydroxymethyl groups: ¹H NMR assignments of the prochiral C-5' protons of 2'-deoxy-ribonucleosides. *Magn Reson Chem* 1990;28(04):24–330
- Soubias O, Jolibois F, Réat V, Milon A. Understanding sterol-membrane interactions, part II: complete ¹H and ¹³C assignments by solid-state NMR spectroscopy and determination of the hydrogen-bonding partners of cholesterol in a lipid bilayer. *Chemistry* 2004;10(23):6005–6014
- D'Amore C, Di Leva FS, Sepe V, et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. *J Med Chem* 2014;57(03):937–954
- Kontiza I, Abatis D, Malakate K, Vagias C, Roussis V. 3-Keto steroids from the marine organisms *Dendrophyllia cornigera* and *Cymodocea nodosa*. *Steroids* 2006;71(02):177–181
- Iverson CD, Zahid S, Li Y, Shoqafi A, Ata A, Samarasekera R. Glutathione S-transferase inhibitory, free radical scavenging, and anti-leishmanial activities of chemical constituents of *Arto-carpus nobilis* and *Matricaria chamomilla*. *Phytochem Lett* 2010; 3(04):207–211
- Abegaz BM, Herz W. A nor-monoterpene from *Artemisia schimperi*. *Phytochemistry* 1991;30(03):1011–1012
- Katade SR, Pawar PV, Tungikar VB, et al. Larvicidal activity of bis(2-ethylhexyl) benzene-1,2-dicarboxylate from *Sterculia guttata* seeds against two mosquito species. *Chem Biodivers* 2006;3(01):49–53
- Dissanayake AA, Wagner CM, Nair MG. Chemical characterization of lipophilic constituents in the skin of migratory adult sea lamprey from the Great Lakes region. *PLoS One* 2016;11(12):e0168609
- Kikuchi M, Yaoita Y, Kikuchi M. Monohydroxy-substituted polyunsaturated fatty acids from *Swertia japonica*. *Helv Chim Acta* 2008;91(10):1857–1862
- Zhang XJ, Zhong WM, Liu RX, et al. Structurally diverse labdane diterpenoids from *Leonurus japonicus* and their anti-inflammatory properties in LPS-induced RAW264.7 cells. *J Nat Prod* 2020; 83(09):2545–2558
- Gao Z, Wang MX, Gao CL, Chen S, Li XW. New glycerolipids from the traditional Chinese Medicine of *Syngnathus acus* (Hai-Long). *Chem Biodivers* 2023;20(06):e202300616